托利珠单抗对硬皮病是有效的,按照新标准衡量。
参考文献
[1]Distler O, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Eng J Med. Published 20 May, 2019. NEJM.org. DOI:10.1056/NEJMoa1903076
[2]Distler O, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Eng J Med. Published 20 May, 2019. NEJM.org. DOI:10.1056/NEJMoa1903076
[3]Cottin V, et al. Interstitial lung disease associated with system icsclerosis (SSc-ILD). Respir. Res. 2019;20(1):13
[4]Denton CP, Khanna D. Systemic sclerosis. 网页链接 Published 13 April, 2017 网页链接(17)30933-9. Last accessed March 2019.
[5]Solomon JJ, et al. European Respiratory Update: Scleroderma lung disease. Eur. Respir. Rev. 2013; 22: 127, 6–19.
$和黄医药(HCM.US)$$中国生物制药(01177.HK)$$恒瑞医药(600276.SH)$
托利珠单抗对硬皮病是有效的,按照新标准衡量。